Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Combinations in Advanced Renal Cell Carcinoma (FRACTION-RCC)
NCT02996110Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2017
- Primary completion
- Nov 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of relatlimab, linrodostat and BMS-813160 in renal cell carcinoma (RCC) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Objective Response Rate up to 247 weeks, Duration of Response up to 247 weeks and 1 more. Started Feb 2017; status: completed.
02
Drugs
relatlimablinrodostatBMS-813160
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02996110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996110.